J Korean Med Sci.  2021 Aug;36(31):e223. 10.3346/jkms.2021.36.e223.

Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea

• Choi JK
• Kim S
• Kim SR
• Jin JY
• Choi SW
• Kim H
• Yoo JH
• Park IS
• Kim SR

• KMID: 2519202
• DOI: http://doi.org/10.3346/jkms.2021.36.e223

Abstract

Vaccination with an adenoviral vector vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can result in the rare development of thrombosis with thrombocytopenia mediated by platelet-activating antibodies against platelet factor 4 (PF4). This is a life-threating condition that may be accompanied by bleeding due to thrombocytopenia with thrombosis of the cerebral venous sinus or splanchnic vein. Herein, we describe the first fatal case of thrombosis with thrombocytopenia syndrome in Korea, presenting with intracranial hemorrhage caused by cerebral venous sinus thrombosis. A 33-year-old Korean man received the first dose of the ChAdOx1 nCoV-19 vaccination. He developed severe headache with vomiting 9 days after the vaccination. Twelve days after vaccination, he was admitted to the hospital with neurological symptoms and was diagnosed with cerebral venous sinus thrombosis, which was accompanied by intracranial hemorrhage. Thrombocytopenia and D-dimer elevation were observed, and the result of the PF4 enzymelinked immunosorbent assay antibody test was reported to be strongly positive. Despite intensive treatment, including intravenous immunoglobulin injection and endovascular mechanical thrombectomy, the patient died 19 days after vaccination. Physicians need to be aware of thrombosis with thrombocytopenia syndrome (TTS) in adenoviral vector-vaccinated patients. Endovascular mechanical thrombectomy might be a useful therapeutic option for the treatment of TTS with cerebral venous sinus thrombosis.

Keyword

COVID-19 Vaccines; Platelet Factor 4; Intracranial Sinus Thrombosis; Endovascular Procedures; Mechanical Thrombolysis

Figure

• 

  Fig. 1 Brain CT, MR venogram, and DSA. (A) Axial image of initial non-enhanced brain CT identifies a 5 × 4 × 3-cm3-sized subcortical hematoma in left parietal lobe and an adjacent subarachnoid hemorrhage, which suggests hemorrhagic venous infarction. (B) The lateral view of the MR venogram only demonstrates the left sigmoid sinus and internal jugular vein (arrows), and the remaining dural venous sinus are not visualized. Deep venous drainage systems, such as the internal cerebral vein and great cerebral vein of Galen (arrow heads), can be identified. (C) AP view of DSA performed before mechanical thrombectomy shows multiple filling defects in the right and left transverse sinus (arrows). (D) The lateral view of superior sagittal sinus venography shows a hardly visualized superior sagittal sinus and blockage of the venous outflow to transverse sinus because of extensive thrombosis in the dural venous sinus. Cortical venous reflux due to blockage of venous outflow in superior sagittal sinus was also noted (arrowheads). (E) Lateral view of the superior sagittal sinus venography after endovascular mechanical thrombectomy shows that venous outflow of superior sagittal sinus and transverse sinus was completely restored. (F) A large number of clots which were removed through endovascular mechanical thrombectomy.CT = computed tomography, MR = magnetic resonance, DSA = digital subtraction angiography, AP = antero-posterior.

Reference

1. Yoo JH. What we do know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021. J Korean Med Sci. 2021; 36(6):e54. PMID: 33559409.

2. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021; 384(22):2092–2101. PMID: 33835769.

3. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021; 384(23):2202–2211. PMID: 33861525.

4. Franchini M, Liumbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol. 2021; 107(2):173–180. PMID: 33987882.

5. Huh K, Na Y, Kim YE, Radnaabaatar M, Peck KR, Jung J. Predicted and observed incidence of thromboembolic events among Koreans vaccinated with ChAdOx1 nCoV-19 vaccine. J Korean Med Sci. 2021; 36(27):e197. PMID: 34254476.

6. Nicolai L, Leunig A, Pekayvaz K, Anjum A, Riedlinger E, Eivers L, et al. Thrombocytopenia and splenic platelet directed immune responses after intravenous ChAdOx1 nCov-19 administration. bioRxiv. Forthcoming. 2021; DOI: 10.1101/2021.06.29.450356.

7. Lee SK, Mokin M, Hetts SW, Fifi JT, Bousser MG, Fraser JF. Society of NeuroInterventional Surgery. Current endovascular strategies for cerebral venous thrombosis: report of the SNIS Standards and Guidelines Committee. J Neurointerv Surg. 2018; 10(8):803–810. PMID: 29871990.

8. Ilyas A, Chen CJ, Raper DM, Ding D, Buell T, Mastorakos P, et al. Endovascular mechanical thrombectomy for cerebral venous sinus thrombosis: a systematic review. J Neurointerv Surg. 2017; 9(11):1086–1092. PMID: 28213478.

9. Mowla A, Shakibajahromi B, Shahjouei S, Borhani-Haghighi A, Rahimian N, Baharvahdat H, et al. Cerebral venous sinus thrombosis associated with SARS-CoV-2; a multinational case series. J Neurol Sci. 2020; 419:117183. PMID: 33075595.

10. Lee SK, Kim BS, Terbrugge KG. Clinical presentation, imaging and treatment of cerebral venous thrombosis (CVT). Interv Neuroradiol. 2002; 8(1):5–14. PMID: 20594505.

11. Cattaneo M. Thrombosis with thrombocytopenia syndrome associated with viral vector COVID-19 vaccines. Eur J Intern Med. 2021; 89:22–24. PMID: 34092488.

12. Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol. 2019; 12(8):685–698. PMID: 31274032.

13. Wolf ME, Luz B, Niehaus L, Bhogal P, Bäzner H, Henkes H. Thrombocytopenia and intracranial venous sinus thrombosis after “COVID-19 vaccine AstraZeneca” exposure. J Clin Med. 2021; 10(8):1599. PMID: 33918932.